We are a biotechnology company developing next-generation cancer vaccines and immunotherapies based on advanced nanobiotechnology and immune modulation. Our proprietary ProLNG platform is a cholesterol-conjugated TLR7/8 agonist adjuvant designed to precisely control innate immune activation, delivering robust Th1-biased cellular immunity with an optimized efficacy–safety profile. ProLNG-001 has completed GLP toxicology studies and is being advanced toward clinical development, with an initial focus on ProV-001, a personalized idiotype cancer vaccine for B-cell lymphoma, and potential expansion across B-cell–derived malignancies. In parallel, we are pursuing partnering opportunities for ProLNG as a vaccine adjuvant and immunomodulator to enhance cancer vaccines and immunotherapies, including strategies to convert immunologically “cold” tumors into “hot” tumor microenvironments.